Proteome Sciences set to feed new biomarkers to Dx firms
This article was originally published in Clinica
Executive Summary
A UK company with high-sensitivity technology to analyse proteins and a strong focus on applying this to help partners accelerate development of diagnostic, prognostic and therapeutic products has carved out a unique niche for itself in the life sciences market. Eleanor Malone visited Proteome Sciences to find out more.